Big pharma interest remains, but the mood is fast turning gloomy.
ApexOnco Front Page
Recent articles
The Rosetta Breast-01 phase 3 trial will only evaluate patients with low PD-L1 expression.
First-gen drugs feature in BCL-2 combos, while Jaypirca and BTK degraders apply extra pressure.
A year after paying $55m to license Biotheus’s PD-L1/VEGF, BioNTech is going all in for $800m.
Response rates in relapsed NPM1-mutant AML look slightly worse than before, but QTc prolongation could be the real worry.
AbbVie looks to justify its faith in TeneoOne, and Bristol its phase 3 move with BMS-986393.
Kura will see more combo data, while a new contender from Sumitomo emerges.
Astra squares up to Merck's Curon deal, while Novartis and Galapagos face off in fast-manufactured Car-T.
